Abstract

Apoptotic Effect of Ginnalin A on MDA-MB-231 and MCF7 Human Breast Cancer Cell Lines †

Ebru Avcı *, Canan Eroğlu, Pınar Özden, Hasibe Vural and Ercan Kurar

Department of Medical Biology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya 42060, Turkey

* Correspondence: eavci@konya.edu.tr; Tel.: +90-332-223-7214
† Presented at the 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 8–11 November 2017.

Published: 13 November 2017

Abstract: Breast cancer is the most common type of cancer in women. The aim of this study was to investigate the effects of Ginnalin A (GA), an important phenolic compounds of maple syrup, on apoptosis in MDA-MB-231 and MCF-7 human breast cancer cells. The effect of GA on cell viability was determined by using XTT method. Expressions of genes are important in apoptosis including CASP3, CASP7, CASP8, CASP9, BCL2, BAX, CYCS, FAS and P53 were evaluated by qPCR. IC₅₀ dose of GA was found as 160 μM in MDA-MB-231 and 300 μM in MCF7 cells, for 72 h. According to the qPCR results, a significant increase in the expression of CASP3, CASP8, CASP9, CYCS, FAS and P53 genes was observed as 3.88, 12.11, 4.76, 8.17, 4.27 and 3.31 folds, respectively in MDA-MB-231. In MCF-7 cells, the expression of CASP9 and P53 genes significantly increased to 8.24 and 3.39 folds, respectively, while the expression of BCL2 gene significantly decreased to 1.85 fold, compared with the control group. In conclusion, it is thought that GA demonstrates apoptotic effect by regulating expression of important genes in apoptosis on breast cancer cells. However, further functional analyses are required to clarify its effect on breast cancer.

Keywords: apoptosis; breast cancer; Ginnalin A

Conflicts of Interest: The authors declare no conflict of interest.

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).